Hemoglobin switching protocols in thalassemia - Experience with sodium phenylbutyrate and hydroxyurea

Annals of the New York Academy of Sciences

Volumn 850, Issue , 1998, Pages 80-86

  Dover, George J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; DIURETIC AGENT; ERYTHROPOIETIN; GAMMA GLOBIN; HEMOGLOBIN; HEMOGLOBIN F; HYDROXYUREA; IRON; SODIUM PHENYLBUTYRATE; UNCLASSIFIED DRUG;

ANKLE EDEMA; BETA THALASSEMIA; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; EPIGASTRIC PAIN; ERYTHROCYTE TRANSFUSION; GENETIC TRANSCRIPTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON CHELATION; IRON OVERLOAD; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; SPINAL CORD COMPRESSION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031872837     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1998.tb10465.x     Document Type: Article

References (41)

1. ZURLO M. C., P. DE STEFANO, C. BORGNA-PIONATTI, A. DI PALMA, A. PIGA, C. MELEVENDI, F. DI GREGORJO, M. G. BURATINI & S. TERZOLI. 1989. Survival and causes of death in thalassemia major. Lancet 2: 27.
2. LUCARELLI, G., M. GALIMBERTI, P. POLCHI, E. ANGELUCCI, D. BARONCIANI, C. GIARDLNI, M. ANDREANI, F. AGOSTINELLI, F. ALBERTINI & R. A. CLIFT. 1993. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. New Engl. J. Med. 329: 840.
3. NIENHUIS, A. W., T. J. LEY, R. K. HUMPHRIES, N. S. YOUNG & G. DOVER. 1985. Pharmacological manipulation of fetal hemoglobin synthesis in patients with severe β-thalassemia. Ann. N.Y. Acad. Sci. 445: 198.
4. STAMATOYANNOPOULOS, J. A. & A. W. NIENHUIS. 1992. Therapeutic approaches to hemoglobin switching in treatment of hemoglobinopathies. Annu. Rev. Med. 43: 497.
5. LEY, T. J., J. DESIMONE, N. P. ANAGNOU, G. H. KELLER, R. K. HUMPHRIES, P. HELLER & A. W. NIENHUIS. 1982. 5-Azacytidine selectively increases γ-globin synthesis in a patient with β+ thalassemia. N. Engl. J. Med. 307: 1469.
6. 0-thalassemic patient unable to be transfused due to multiple alloantibodies. Br. J. Hematol. 74: 467.
7. LOWREY, C. H. & A. W. NIENHUIS. 1993. Treatment with azacytidine of patients with end-stage β-thalassemia. N. Engl. J. Med. 329: 845.
8. MCDONAGH, K. T., E. P. ORRINGER, G. J. DOVER & A. W. NIENHUIS. 1990. Hydroxyurea improves erythropoiesis in a patient with homozygous beta thalassemia. Clin. Res. 38: 346A, Abstract.
9. FUCHAROEN, S., N. SIRITANARATKUL, P. WINICHAGOON, W. SIRIBOON, J. CHOWATHAWORN, W. MUANGSUP, S. CHAICHAROEN, N. POOLSUP, B. CHINDAVIJAK, P. POOTRAKUL, A. PIANKIJAGUM, A. N. SCHECHTER & G. P. RODGERS. 1993. Hydroxyurea increases HbF levels and improves the effectiveness of erythropoiesis in β-thalassemia/HbE disease. Blood 82: 357a, Abstract.
10. RACHMILEWITZ, E. A., A. GOLDFARB & G. DOVER. 1991. Administration of erythropoietin to patients with β thalassemia intermedia: A preliminary trial. Blood 78: 1145, Letter.
11. OLIVIERI, N. F., B. SHERIDAN, M. FREEDMAN, G. DOVER, S. PERRINE & R. S. NAGEL. 1992. Trial of recombinant human erythropoietin in thalassemia intermedia. Blood 80: 3258, Letter.
12. ORKIN, S. H., D. SWAN & P. LEDER. 1975. Differential expression of α- and β-globin genes during differentiation of cultured erythroleukemic cells. J. Biol. Chem. 250: 8753.
13. ANDERSON, L. C., M. JOKINEN & C. G. GAHMBERG. 1979. Induction of erythroid differentiation in the human leukemia cell line K562. Nature 278: 364.
14. SAMID, D., S. SHACK & L. T. SHERMAN. 1992. Phenylacetate: A novel nontoxic inducer of tumor cell differentiation. Cancer Res. 52: 1988.
15. PERRINE, S. P., B. A. MILLER, D. V. FALLER, R. A. COHEN, E. P. VICHINSKY, D. HURST, B. H. LUBIN & TH. PAPAYANNOPOULOU. 1989. Sodium butyrate enhances fetal globin expression in erythroid progenitors of patients with HbSS and β-thalassemia. Blood 74: 454.
16. FIBACH, E., P. PRASANNA, G. P. RODGERS & D. SAMID. 1993. Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal blood donors and patients with sickle cell anemia and β-thalassemia. Blood 82: 2203.
17. STAMATOYANNOPOULOS, G., B. NAKAMOTO, B. JOSEPHSON, Q. LI, A. BLAU, E. LIAKAPOULOU, TH. PAPAYANNOPOULOU, S. BRUSILOW & G. DOVER. 1993. Acetate, a product of butyrate catabolism, stimulates γ-globin expression in adult cells in vivo and in culture. Blood 82: 313a, Abstract.
18. PERRINE, S. P., A. RUDOLPH, D. V. FALLER, C. ROMAN, R. A. COHEN, S-J. CHEN & Y. W. KAN. 1988. Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching. Proc. Natl. Acad. Sci. USA 85: 8540.
19. GINDER, G. D., M. J. WHITTERS & J. K. POHLMAN. 1984. Activation of a chicken embryonic globin gene in adult erythroid cells by 5-azacytidine and sodium butyrate. Proc. Natl. Acad. Sci. USA 81: 3954.
20. CONSTANTOULAKIS, P., TH. PAPAYANNOPOULOU & G. STAMATOYANNOPOULOS. 1988. Alpha-amino-N-butyric acid stimulates fetal hemoglobin in the adult. Blood 72: 1961.
21. CONSTANTOULAKIS, P., G. KNITTER & G. STAMATOYANNOPOULOS. 1989. On the induction of fetal hemoglobin by butyrates: In vivo and in vitro studies with sodium butyrate and comparison of combination treatment with 5-azaC and Ara C. Blood 74: 1963.
22. BLAU, C. A., P. CONSTANTOULAKIS, C. M. SHAW & G. STAMATOYANNOPOULOS. 1993. Fetal hemoglobin induction with butyric acid: Efficacy and toxicity. Blood 81: 529.
23. PERRINE, S. P., M. F. GREENE & D. V. FALLER. 1985. Delay in the fetal globin switch in infants of diabetic mothers. New Engl. J. Med. 312: 334.
24. PERRINE, S. P., G. D. GINDER, D. V. FALLER, G. J. DOVER, T. IKUTA, H. E. WITKOWSKA, S-P. CAI, E. P. VICHINSKY & N. F. OLIVIERI. 1993. A short term trial of butyrate to stimulate fetal-globin-gene expression in the β- globin disorders. New Engl. J. Med. 328: 81.
25. SHER, G. D., B. ENTSUAH, G. GINDER, G. DOVER, J. LITTLE, J. DONSKY, M. BERKOVITCH, N. LEWIS, L. CHANG, S. PERRINE & N. F. OLIVIERI. 1993. Intravenous infusion of arginine butyrate increases γ-globin mRNA expression and F-reticulocytes in patients with homozygous β-thalassemia and sickle cell disease. Blood 82: 312a, Abstract.
26. COSTIN, D., G. DOVER, N. OLIVERI, E. BEUTLER, C. T. WALSH, S. TORKELSON, C. PANTAZIS, M. BRAUER, D. V. FALLER & S. P. PERRINE. 1993. Clinical use of the butyrate derivative isobutyramide in the β-globin disorders. Blood 82: 357a.
27. PERRINE, S. P., N. F. OLIVTERI, D. V. FALLER, E. P. VICHINSKY, G. J. DOVER & G. D. GINDER. 1994. Butyrate derivatives: New agents for stimulating fetal globin production in the β-globin disorders. Am. J. Ped. Hem.-Onc. 16: 67.
28. DOVER, G. J., S. W. BRUSILOW & D. SAMID. 1992. Increased fetal hemoglobin in patients receiving sodium 4-Phenylbutyrate. New Engl. J. Med. 327: 569. Letter.
29. DOVER, G. J., S. W. BRUSILOW & S. CHARACHE. 1994. Induction of HbF production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 84: 339.
30. LITTLE, J., M. TUCHMAN & G. D. GINDER. 1994. Elevated fetal hemoglobin levels in propionic acidemia. Clin. Res. 42: 238A. Abstract.
31. PERRINE, S., G. DOVER, D. COSTIN, C. PANTAZIS, S. EMBURY , G. LAZZARI, E. VICHLNSKY, P. DAFTARI, A. XIN & N. OLIVIERI. 1993. Correction of globin chain imbalance in thalassemia major by arginine butyrate therapy. Blood 82: 312a, Abstract.
32. BRUSILOW, S. W. 1991a. Treatment of urea cycle disorders. In Treatment of Genetic Disease. R. J. Desnick, Ed.: 79. Churchill-Livingstone.
33. Coulter Electronics. 1985. How to handle abnormal blood results for Coulter Counter instruments. Coulter Education Center, Miami FL 33014. September.
34. TICHELLI, A., A. GRATHWOHL, A. DRIESSEN, S. MATHYS, E. PFEFFERKORN, A. REGENASS, P. SCHUMACHER, C. STEBLER, M. WERNLI, C. NISSEN & B. SPECK. 1990. Evaluation of the Sysmex R-1000: An automated reticulocyte analyzer. J. Clin. Path. 93: 70.
35. DOVER, G. J., S. H. BOYER & W. R. BELL. 1978. Microscopic method for assaying F-cell production: Illustrative changes during infancy and aplastic anemia. Blood 52: 664.
36. HUISMAN, T. H. J. & J. H. P. JONXIS. 1977. The hemoglobinopathies: Techniques of identification. In Clinical and biochemical analysis. Vol 6: 192. M. K. Schwartz, Ed. N. Y., New York. Marcel Dekker Inc.
37. BRUSILOW, S. W. 1991b. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr. Res. 29: 147.
38. EISNER, T., W. E. CONNER, K. HICKS, K. R. DODGE, K. R. ROSENBERG, T. H. JONES, M. COHEN & J. MEINWALD. 1977. Sunk of stinkpot turtle identified: Phenylalkanoic acids. Science 196: 1347.
39. DOVER G. J., K. D. SMITH, Y. C. CHANG, S. PURVIS, A. MAYS, D. A. MEYERS, C. SHEILS & G. SERJEANT. 1992. Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2. Blood 80: 816.
40. THEIN, S. L., M. SAMPIETRO, K. ROHDE, J. ROCHETTE, D. J. WEATHERALL, G. M. LATHROP & F. DEMENAIS. 1994. Detection of a major gene for heterocellular hereditary persistence of fetal hemoglobin after accounting for genetic modifiers. Am. J. Hum. Genet. 54: 214.
41. GALANELLO, R., S. BARELLA, M. P. TURCO, N. GIAGU, A. CAO, F. DORE, N. L. LIBERATO, R. GUARNONE & G. BAROSI. 1994. Serum erythropoietin and erythropoiesis in high- and low-fetal hemoglobin β-thalassemia intermedia patients. Blood 83: 561.